Cargando…
Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.
Human solid tumours are composed of a significant proportion of hypoxic cells, i.e. cells with oxygen levels lower than those of normal tissues. Tumour hypoxic cells have been shown to have a negative impact on the response of solid tumours to radiation therapy and chemotherapy. However, these low c...
Autor principal: | Brown, J. M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2149884/ https://www.ncbi.nlm.nih.gov/pubmed/9647614 |
Ejemplares similares
-
SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
por: Brown, J. M.
Publicado: (1993) -
Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin
por: Kovacs, M S, et al.
Publicado: (1999) -
Tirapazamine-cisplatin: the synergy.
por: Gatzemeier, U., et al.
Publicado: (1998) -
Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine.
por: Olive, P. L.
Publicado: (1995) -
Improving Tirapazamine (TPZ) to Target and Eradicate Hypoxia Tumors by Gold Nanoparticle Carriers
por: Ajnai, Giimel, et al.
Publicado: (2022)